Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-GPNMB, CDX-011 (DOX) Vector   (CAT#: GTVCR-WQ956MR)

This product GTVCR-WQ956MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting GPNMB. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Homo sapiens
RefSeq NM_001005340.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-GPNMB, CDX-011 (DOX) Vector (GTVCR-WQ956MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ002MR IVTScrip™ pT7-VEE-mRNA-EGFP Vector Vector EGFP
GTVCR-WQ492MR IVTScrip™ pT7-VEE-mRNA-Anti-IL17RA, AMG827 Vector Vector AMG827
GTVCR-WQ901MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD38, CD38-Attenukine Vector Vector CD38-Attenukine
GTVCR-WQ896MR IVTScrip™ pT7-VEE-mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1) Vector Vector CD20-TCB (2:1)
GTVCR-WQ1378MR IVTScrip™ pSP6-VEE-mRNA-Anti-SLC39A6, hLIV22 Vector Vector hLIV22
GTVCR-WQ1700MR IVTScrip™ pT7-VEE-mRNA-Anti-CGRP, LBR-101 Vector Vector LBR-101
GTVCR-WQ1348MR IVTScrip™ pT7-VEE-mRNA-Anti-F, H1H3592P3 Vector Vector H1H3592P3
GTVCR-WQ264MR IVTScrip™ pT7-VEE-mRNA-Anti-MSTN, ACE-031 Vector Vector ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW